EOM Pharmaceutical (PK)【IMUC】銘柄情報

EOM Pharmaceutical Holdings Inc (PK) (IMUC) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.20

( - )

買値

0.20

売値

0.2699

出来高

115

平均取引量 (3 か月)

US$ 12,118

財務取引量

US$ 23

0.20 日の範囲 0.20

0.036 52 週間の範囲 0.3399

時価総額

25.301M

企業価値

前日終値

0.20

始値

0.20

時刻

0.217475

最終取引時間

02:22:25

VWAP

0.20

歳入

純利益

-5.13M

発行済株式数

126,502,860

浮動株比率 (%)

機関投資家保有比率 (%)

配当利回り

PER

-3.77

株価売上高倍率 (PSR)

1 株当たり利益 (EPS)

-0.05

ベータ

0.15

EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a pe... EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as well as in Phase ½ a clinical trial to treat infectious diseases, such as COVID-19. It also develops EOM 147, an investigational broad-spectrum aminosterol with an intracellular mechanism that has completed Phase 2 clinical trial for the treatment of age-related macular degeneration, diabetic retinopathy, and macular edema due to retinal vain occlusion. EOM Pharmaceuticals Holdings, Inc. was founded in 2020 and is headquartered in Montvale, New Jersey. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

eompharma.com

本社

Montvale, United States

設立

2026

EOM Pharmaceutical Holdings Inc (PK) is listed in the Healthcare sector of the その他OTC with ticker IMUC. The last closing price for EOM Pharmaceutical (PK) was US$0.20. Over the last year, EOM Pharmaceutical (PK) shares have traded in a share price range of US$ 0.036 to US$ 0.3399.

EOM Pharmaceutical (PK) currently has 126,502,860 shares in issue. The market capitalisation of EOM Pharmaceutical (PK) is US$25.30 million. EOM Pharmaceutical (PK) has a price to earnings ratio (PE ratio) of -3.77.

Form RW - Registration Withdrawal Request

ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing Standards

ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing...

ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock Warrants

ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock...

ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial...

ImmunoCellular Therapeutics Announces Agreement on Terms of Settlement of Federal Class Action Shareholder Lawsuit

ImmunoCellular Therapeutics Announces Agreement on Terms of Settlement of Federal Class Action Shareholder...

ImmunoCellular Therapeutics Announces First Quarter 2018 Financial Results

ImmunoCellular Therapeutics Announces First Quarter 2018 Financial Results -Continued Progress in...

ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program

ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research...

ImmunoCellular Therapeutics Receives Audit Opinion with Going Concern Explanation

ImmunoCellular Therapeutics Receives Audit Opinion with Going Concern Explanation PR Newswire LOS ANGELES...

ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results

ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results -Continued Progress...

ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018

ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018 PR...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0699	-25.8984809189	0.2699	0.2699	0.2	292	0.20958629	CS
4	-0.0699	-25.8984809189	0.2699	0.27	0.1901	2846	0.23586749	CS
12	0.081212	68.3671751355	0.118788	0.27	0.075	12119	0.15688485	CS
26	0.09	81.8181818182	0.11	0.27	0.075	8201	0.14024541	CS
52	0.1329	198.062593145	0.0671	0.3399	0.036	9964	0.11982285	CS
156	-0.18	-47.3684210526	0.38	0.3999	0.0123	6093	0.14835472	CS
260	-0.39005	-66.1045674095	0.59005	0.94	0.0123	6631	0.30205759	CS